Two-Drug sequence aims to clear CLL cells and let patients stop treatment
Disease control
Not yet recruiting
This phase 2 trial tests a treatment plan for people with newly diagnosed chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Participants first take zanubrutinib alone for 12 cycles, then add sonrotoclax for another 12 cycles. The goal is to see if this seque…
Phase: PHASE2 • Sponsor: Yi Shuhua • Aim: Disease control
Last updated Jul 03, 2026 19:21 UTC